…I would conclude that the ACHN drugs are not nukes.
Correct.
Therefore, is the ACHN pipeline complementary rather than competitive with GILD/BMY?
ACHN’s drugs are potentially complementary; however, the more immediate concern—and the reason ACHN is down today—is that the results reported today by GILD and BMY may lessen the need for these companies to seek complementary agents.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”